BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus

BAFF, a member of the TNF superfamily, has been recognized as a good target for autoimmune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Shin, Woori, Lee, Hyun Tae, Lim, Heejin, Lee, Sang Hyung, Son, Ji Young, Lee, Jee Un, Yoo, Ki-Young, Ryu, Seong Eon, Rhie, Jaejun, Lee, Ju Yeon, Heo, Yong-Seok
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865148/
https://ncbi.nlm.nih.gov/pubmed/29572471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03620-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados